← Leaderboards
Vivek Subbiah
University Of Oklahoma Hlth Sciences Ctr
$600,026
Attributed
$1,800,077
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $994.9K · FY2020–22$1M$750K$500K$250K$0
'20
'21
'22
Funding mix
By agency
NIH$1,800,077 · 2
By mechanism
R01$1,800,077 · 2
Top collaborators
- Jie Wu4 shared
- Blaine H. M. Mooers3 shared
- Herman O Sintim1 shared
Most similar at University Of Oklahoma Hlth Sciences Ctr
Same institution · by research overlap
- Youngjae You$4,324,163
- Adam Zlotnick$11,682,701
- Blaine H. M. Mooers$2,541,882
- Weidong Wang$5,503,980
- Jordi Rodon Ahnert$390,833
Others in their field
Other Emerging Leaders on “Protein Tyrosine Kinase”
- Steve Lim · University Of South Alabama$4,942,628
- Yi Ye · New York University$4,914,870
- Timothy A Marlowe · University Of Arizona$4,884,563
- Gian Luca Araldi · Avanti Biosciences, Inc.$4,714,980
- Patricio Sepulveda · Amplo Biotechnology, Inc.$4,712,014
- Thimmasettappa Thippeswamy · Iowa State University$4,666,151
Research focus
Protein Tyrosine KinaseTransgenic MiceMutantPhosphotransferasesResistanceTransfectionLung NeoplasmsMalignant NeoplasmsMutationPharmaceutical PreparationsBaseCancer TherapyResponseTargeted TreatmentGenesIn VivoMalignant Neoplasm Of ThyroidClinical DevelopmentBypassDrug ResistanceNon-Small-Cell Lung CarcinomaOncogenesCancer PatientTreatment Response
Grant awards (4)
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold$612,099
R01 · FY2022 · CA
Blocking tumor progression in therapy-responsive RET aberration-associated cancer$382,759
R01 · FY2022 · CA
Blocking tumor progression in therapy-responsive RET aberration-associated cancer$391,096
R01 · FY2021 · CA
Blocking tumor progression in therapy-responsive RET aberration-associated cancer$414,123
R01 · FY2020 · CA